DIPROMON
"Multimodular biomarker analysis workflow for diagnosis, prognosis and monitoring of drug treatment response in bladder cancer"
| Coordinatore | UNIVERSITY OF SURREY
Organization address
address: Stag Hill contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 4˙596˙144 € |
| EC contributo | 3˙492˙216 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2012-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-11-01 - 2016-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY OF SURREY
Organization address
address: Stag Hill contact info |
UK (GUILDFORD) | coordinator | 704˙168.50 |
| 2 |
LIONEX GMBH
Organization address
address: Salzdahlumer Strasse 196 contact info |
DE (BRAUNSCHWEIG) | participant | 896˙984.00 |
| 3 |
ONKOTEC GMBH
Organization address
address: VESTENOTTING 1 contact info |
AT (WAIDHOFEN AN DER THAYA) | participant | 643˙068.00 |
| 4 |
AXO SCIENCE SAS
Organization address
address: RUE DU MAIL 34 contact info |
FR (LYON) | participant | 520˙700.00 |
| 5 |
EMERGENTEC BIODEVELOPMENT GMBH
Organization address
address: GERSTHOFER STRASSE 29-31 contact info |
AT (VIENNA) | participant | 370˙602.00 |
| 6 |
AIT Austrian Institute of Technology GmbH
Organization address
address: Donau-City-Strasse 1 contact info |
AT (WIEN) | participant | 356˙694.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'With the advent of Omics technologies capable of profiling substantial fractions of molecular entities from the genome down to the metabolome level a significant boost in understanding disease pathophysiology, consequently providing tailored diagnostics and therapy, was expected. With impressive results for selected diseases, cancer still sees significant shortcomings. One reason for this clinical situation is certainly the apparent heterogeneity of cancers, manifesting in clinical presentation and outcome, but also on the personalized molecular level. Within DIPROMON we selected bladder cancer as a prototypical example for the need of personalization efforts in therapy, and we plan of using this clinically highly challenging disease phenotype for establishing a general workflow for enabling personalization strategies towards rational decision on tailoring therapeutic interventions for defined patient groups. DIPROMON on its basis follows a computational Systems Biology approach for delineating statistical rules for patient segmentation, resting on patient-specific biomarker profiles interpreted in tight integration with patient-specific clinical data. DIPROMON will establish a workflow including quality control aspects for i) selecting biomarker panels for given clinical phenotypes, ii) providing modular instrumentation for measuring the profiles in a clinical setting, and iii) deriving statistics-driven rules for patient segmentation regarding optimal therapy. DIPROMON will finally validate the concept in bladder cancer.'